Generalizing the per-protocol treatment effect: The case of ACTG A5095 by Lu, H. et al.
Generalizing the per-protocol
treatment effect: The case of
ACTG A5095
Haidong Lu1, Stephen R Cole1, H Irene Hall2, Enrique F Schisterman3,
Tiffany L Breger1, Jessie K Edwards1 and Daniel Westreich1
Abstract
Background: Intention-to-treat comparisons of randomized trials provide asymptotically consistent estimators of the
effect of treatment assignment, without regard to compliance. However, decision makers often wish to know the effect
of a per-protocol comparison. Moreover, decision makers may also wish to know the effect of treatment assignment or
treatment protocol in a user-specified target population other than the sample in which the trial was fielded. Here, we
aimed to generalize results from the ACTG A5095 trial to the US recently HIV-diagnosed target population.
Methods: We first replicated the published conventional intention-to-treat estimate (2-year risk difference and hazard
ratio) comparing a four-drug antiretroviral regimen to a three-drug regimen in the A5095 trial. We then estimated the
intention-to-treat effect that accounted for informative dropout and the per-protocol effect that additionally accounted
for protocol deviations by constructing inverse probability weights. Furthermore, we employed inverse odds of sampling
weights to generalize both intention-to-treat and per-protocol effects to a target population comprising US individuals
with HIV diagnosed during 2008–2014.
Results: Of 761 subjects in the analysis, 82 dropouts (36 in the three-drug arm and 46 in the four-drug arm) and 59 protocol
deviations (25 in the three-drug arm and 34 in the four-drug arm) occurred during the first 2 years of follow-up. A total of 169
subjects incurred virologic failure or death. The 2-year risks were similar both in the trial and in the US HIV-diagnosed target
population for estimates from the conventional intention-to-treat, dropout-weighted intention-to-treat, and per-protocol analy-
ses. In the US target population, the 2-year conventional intention-to-treat risk difference (unit: %) for virologic failure or death
comparing the four-drug arm to the three-drug arm was 20.4 (95% confidence interval: 26.2, 5.1), while the hazard ratio was
0.97 (95% confidence interval: 0.70, 1.34); the 2-year risk difference was 20.9 (95% confidence interval: 26.9, 5.3) for the
dropout-weighted intention-to-treat comparison (hazard ratio = 0.95, 95% confidence interval: 0.68, 1.32) and 20.7 (95% con-
fidence interval: 26.7, 5.5) for the per-protocol comparison (hazard ratio = 0.96, 95% confidence interval: 0.69, 1.34).
Conclusion: No benefit of four-drug antiretroviral regimen over three-drug regimen was found from the conventional
intention-to-treat, dropout-weighted intention-to-treat or per-protocol estimates in the trial sample or target population.
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Introduction
Randomized controlled trials are considered the gold
standard for causal inference in medical interventions.
This is primarily because randomization eliminates
confounding by design and therefore helps to ensure
internal validity by making treatment groups compara-
ble (or exchangeable) in expectation. The standard
approach to the analysis of randomized trials, the
intention-to-treat (ITT) comparison, provides an
asymptotically consistent effect estimate of the treat-
ment assignment.1–3 Yet, those making treatment
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decisions often want to know the effect of the treatment
assigned under adherence to the treatment protocol
(i.e. the per-protocol comparison).4,5 Asymptotically
consistent estimates of the per-protocol effect (account-
ing for protocol deviations (e.g. non-compliance)) can
be obtained by censoring patients at protocol deviation
and using inverse probability (IP) weights under the
additional assumption that the common causes of the
endpoint and protocol deviations are measured and the
model correctly specified.6 For example, recently
Murray and Hernán7 estimated a per-protocol effect
on mortality in the placebo arm of the Coronary Drug
Project by standardizing on pre- and post-
randomization covariates using IP weighting.
In addition, lack of external validity is a major con-
cern in medical research and randomized trials.8,9
External validity refers to the extent that results gener-
alize to a specified target population. In a randomized
trial, generalizability is often limited, and external
validity is constrained due to restrictive inclusion and
exclusion criteria. Recently, there have been several
quantitative methods developed to enhance external
validity.10–16 Asymptotically consistent estimates of the
generalized treatment effect can be obtained also using
IP of sampling weights under the additional assump-
tion that the common causes of the endpoint and deter-
minants of sampling into the trial are measured and the
model correctly specified.9,13,17
The AIDS Clinical Trials Group (ACTG), estab-
lished in 1987, is a paragon of modern clinical trial
research. ACTG studies have made major contributions
to optimizing HIV treatment. One exemplar ACTG
study is the A5095 trial, which compared the efficacy
and safety of a standard three-drug antiretroviral ther-
apy (ART) regimen (zidovudine, lamivudine, efavirenz)
versus adjuvant therapy regimen with abacavir (zidovu-
dine, lamivudine, efavirenz, and abacavir) among HIV-
infected adults with viral load of at least 400 copies/mL
at randomization.18 An ITT analysis found no signifi-
cant difference in time to virologic failure between
three-drug and four-drug regimens (hazard ratio
=0.95; 97.5% confidence interval (CI): 0.69, 1.33).
However, like many randomized trials, the A5095 trial
suffered from 20% dropout and 17% protocol devia-
tions (i.e. non-compliance to the assigned treatment).18
In this setting, an ITT estimator may produce biased
estimates of the per-protocol effect (i.e. the effect if
everyone initiated and followed the protocol over the
entire follow-up) and may be inadequate for the assess-
ment of comparative effectiveness.4,19,20 Therefore, a
per-protocol analysis that accounts for protocol devia-
tions would complement the published ITT results. In
addition, the existing A5095 ITT results and per-
protocol results may not generalize to the target popu-
lation of US HIV-diagnosed persons. For example, the
A5095 study sample included 35% African American
patients and 9% patients under 26 years of age
compared with about 45% and 20%, respectively, in
the annual HIV-diagnosed population in the United
States as defined using national HIV surveillance data
by the Centers for Disease Control and Prevention
(CDC).21 If race and age are potential modifiers of the
treatment effect on virologic failure, we may be con-
cerned about such covariate imbalances, as they may
pose a threat to the external validity of the trial results.
Here, we first replicate the ITT estimate for the
effect of assigned treatment published with the A5095
results.18 Next, we estimate the per-protocol effect of
the treatment plan. Then, we generalize both the ITT
and per-protocol effect estimates to persons diagnosed
with HIV in the United States during 2008–2014 as
defined by CDC national surveillance data.
Methods
The ACTG A5095 study
The ACTG A5095 study was a three-arm randomized
double-blind, placebo-controlled clinical trial designed
to compare three antiretroviral regimens for treatment
of HIV-1 infection.18,22 Between March 2001 and
November 2002, 1147 HIV-1-infected patients were
enrolled and randomly assigned 1:1:1 to one of three
antiretroviral regimens: a triple-nucleoside regimen (i.e.
zidovudine, lamivudine, and abacavir), a three-drug
standard-of-care-regimen (i.e. zidovudine, lamivudine,
and efavirenz), or a novel four-drug regimen (i.e. zido-
vudine, lamivudine, efavirenz, and abacavir). Eligible
patients had received no previous ART and had a
plasma HIV-1 RNA level of at least 400 copies/mL.
Excluded patients had received immunomodulatory or
investigational therapy or vaccines within the previous
month, weighed \40 kg, or were pregnant or breast-
feeding. In 2003, the triple-nucleoside regimen was dis-
continued due to inferiority.22 As in the primary
report,18 here we disregard the triple-nucleoside regi-
men and compare the novel four-drug regimen to the
three-drug standard-of-care regimen. For the present
analysis, we used the public A5095 data set available
from the National Technical Information Service
(NTIS) (http://www.ntis.gov/).
In the published study, the primary endpoint was
time from randomization to virologic failure; here, we
take the primary endpoint to be time to virologic failure
or death from any cause. Virologic failure was defined
as the time of the first of two successive HIV-1 RNA
levels of 200 or more copies/mL, at least 16 weeks after
randomization. Follow-up visits occurred at weeks 2, 4,
8, 12, 16, 20, and 24 and then every 8 weeks until end
of study in March 2005. While the longest recorded
follow-up was 204 weeks, here we administratively cen-
sor patients at 2 years (730 days). Four patients were
excluded from analysis because of inconsistencies in the
public-use data. This work was judged not to be human
subjects research by the University of North Carolina
Institutional Review Board.
Intention-to-Treat Effect
Let uppercase letters represent random variables, and
lowercase letters represent possible realizations of ran-
dom variables or constants. Let i index the n study
patients and t index the up to 2 years (730 days) from
randomization. Let Ri = 1 denote that patient i was
randomized to the four-drug regimen, and Ri = 0
denote randomization to the three-drug regimen. Let
Dit = 1 indicate the primary endpoint for patient i by
day t from randomization. Let Dit = 1 indicate dropout
(i.e. defined as loss to follow-up before completing the
study protocol) for patient i by day t from randomiza-
tion. The conventional ITT hazard ratio assumes inde-
pendent censoring (i.e. the censoring mechanism is
independent of the survival time given treatment assign-
ment). It was estimated from standard Cox propor-
tional hazards model.23 The parameters of this Cox
model were estimated by maximizing the partial likeli-
hood.24 Assuming no tied survival times, the partial
likelihood corresponding to patient i experiencing end-
point on day t is
exp b̂ITT , SRi
 
P
j2J tð Þexp b̂ITT , SRj
 
where J (t) is the risk set on day t, exp (b̂ITT , S) is the esti-
mator of the conventional sample ITT hazard ratio of
virologic failure or death comparing assignment to the
four-drug regimen to assignment to the three-drug regi-
men in the A5095 trial. We used Efron’s method for
tied survival times.25
Next, to account for potential dependent censoring
due to dropout (i.e. informative dropout), we standar-
dized the ITT hazard ratio to the study sample at ran-
domization (i.e. before dropouts occurred) using IP of
censoring weights.6,26 Let Wit be a vector of time-fixed
(i.e. where t= 0) and time-varying covariates. Time-
fixed covariates included sex, age at randomization,
baseline hepatitis B virus/hepatitis C virus (HBV/HCV)
infection status, and baseline viral load (copies/mL)
and baseline CD4 cell count (cells/mm3). Time-varying
covariates, used to account for informative dropout,
included CD4 counts, viral load, first diagnosis of an
HIV-related disease, and the presence of severe or life-
threatening adverse events (i.e. National Institute of
Allergy and Infectious Diseases Division of AIDS toxi-
city scale grade 3 or 427) during the follow-up visits.
Restricted quadratic splines with four knots at 5th,
35th, 65th, and 95th percentiles were used to model
CD4 cell count and viral load.28,29
Let Wit = fWi0,Wi1, . . . ,Witg be the covariate his-





P Dik = 0jDi k1ð Þ= 0,Ri
 
P Dik = 0jDi k1ð Þ= 0,Ri, W i k1ð Þ
 
where Di(1) and Wi(1) are defined to be Di0 and Wi0.
30
Here, we did not include baseline covariates in the
numerator of the weight and solely stabilized on the
probability of treatment so as to allow presentation of
marginal survival functions. The numerator and
denominator of these stabilized weights were estimated
by pooled logistic regression fit by maximum likelihood
with models
logit P(Dit = 0jDi t1ð Þ= 0,Ri)=a0t +a1Ri and







W i t1ð Þ
where a02 is the transpose of column vector of log odds
ratios for the covariate history Wi(t1). Specifically, in a
pooled logistic regression, each person-visit was consid-
ered as an observation, and the model was fit using per-
son-visits.31 The denominator of each term in p̂Dit is the
probability that a patient i remained uncensored at time
t given his or her past exposure and covariate history
and that he or she remained uncensored in the previous
visits.
Then the ITT hazard ratio was estimated by partial
likelihood, IP weighted to account for informative
dropout.31 The weighted partial likelihood was maxi-
mized, where patient i who incurred virologic failure or
death at day t from randomization contributed the
term









where exp (~bITT , S) is the estimator of the ITT hazard
ratio of virologic failure or death comparing assign-
ment to the four-drug regimen to assignment to the
three-drug regimen in the trial sample. This estimator
accounts for potential informative dropout, under the
assumption that the patients who dropped out on day t
are exchangeable with those who remained in the study
on day t conditional on prognostic factors Wit.
30 Here
and below, we also assume positivity, namely, there is a
nonzero probability of being observed for every combi-
nation of values of treatment and covariate histories.32
Throughout, for identification of effects, we also
assume that there is no interference between sub-
jects,33,34 that any versions of treatment are irrele-
vant,35 negligible measurement error, and that models
are correctly specified. The standard error for IP-
weighted hazard ratio was estimated using robust sand-
wich variance.
In addition, for each study arm, conventional ITT
risks and dropout-weighted ITT risks of the primary
endpoint (i.e. virologic failure or death) were estimated
using the Kaplan–Meier method36 and the inverse
probability-weighted Kaplan–Meier method.37 The two
arms were also compared using a 2-year risk difference.
The CIs for risks, weighted risks, and risk difference
were obtained with the standard error estimated by
the standard deviation of 200 nonparametric bootstrap
samples with replacement of the total study sample
size n.38
Per-protocol effect
To estimate the per-protocol effect for continuous use
of the four-drug regimen compared with the continu-
ous use of the three-drug regimen, we account for pro-
tocol deviations as well as informative dropout.6,39 The
estimation of the per-protocol effect was similar to that
for the ITT effect accounting for informative dropout,
except that Cit is used to denote censoring at the mini-
mum of dropout or a protocol deviation by day t from
randomization, rather than Dit denoting censoring at
dropout alone previously. Then, we estimated stabilized




P Cik = 0jCi k1ð Þ= 0,Ri
 
P Cik = 0jCi k1ð Þ= 0,Ri, W i k1ð Þ
 
where Ci(1) and Wi(1) are defined to be Ci0 and Wi0.
The numerator and denominator of these stabilized
weights were estimated by pooled logistic regression fit
by maximum likelihood with models
logit P Cit = 0jCi t1ð Þ= 0,Ri
 
=g0t + g1Ri and







W i t1ð Þ
where g02 is the transpose of column vector of log odds
ratios for the covariate history Wi(t1).
The per-protocol hazard ratio was estimated by par-
tial likelihood, IP weighted to account for potential
informative dropout and protocol deviations.31 The
weighted partial likelihood was maximized, where
patient i who incurred virologic failure or death at day










where exp (b̂PP, S) is now the per-protocol hazard ratio
of virologic failure or death comparing continually
received four-drug regimen to continually received
three-drug regimen in the trial sample. This estimator is
consistent under the assumption that the patients who
incurred protocol deviations on day t are exchangeable
with those who complied with the study protocol on
day t conditional on prognostic factors Wit.
6,30 The per-
protocol risks were also estimated using the IP-
weighted Kaplan–Meier method and risk difference
estimated at year 2 from baseline.
Generalizing effects to a US target population
The target population of size m was defined as the
recently HIV-diagnosed population in the United
States in 2008–2014 based on CDC data.40 To account
for the potential differences between the trial sample
and the specified target population, we employed
inverse odds-of-sampling weights.9 Let i now index the
n+m subjects in the concatenated study sample and
target population (of size m). Let Si = 1 denote selec-
tion into the trial sample of
P
i Si patients, and Si = 0
denote those in the target population. Let Vi be an
(n+m)-by-p matrix of discrete variables that describe
the composition of the sample and target population,
including age, sex, and injection drug use (ever versus
never). Stabilized inverse odds-of-sampling weights for




P(Si = 1jVi) 3
P Si = 1ð Þ
P Si = 0ð Þ Si = 1
0 Si = 0

as described by Westreich et al.16 The odds weights
allow us to estimate the effect in the target population
rather than in the combined population. Here, we use
odds weights because we wish to estimate the effect in
the target population uncorrupted by the trial sample.16
If standard IP of sampling weights10 were employed as
opposed to the odds weights, the estimator would be
standardized to the combination of the target popula-
tion and the trial sample. The numerator and denomi-
nator of these stabilized weights were estimated by
logistic regression fit by maximum likelihood with
models
logit P Si = 1ð Þ= d0 and
logit P Si = 1jVið Þ= d00 + d01Vi
where d01 is the transpose of column vector of log odds
ratios for the composition of the population Vi. Then,
for each subject in the trial sample, we created the total
IP weight





that accounted for informative dropout and sampling
bias for the dropout-weighted ITT hazard ratio estima-
tion in the target US recently HIV-diagnosed popula-
tion and total IP weight





that accounted for informative dropout, protocol devia-
tions, and sampling bias for the per-protocol hazard
ratio estimation in the target population (as well as the
IP weight p̂Si that only accounted for sampling bias for
the conventional ITT hazard ratio estimation in the tar-
get population). Both dropout-weighted ITT and per-
protocol hazard ratios were estimated by IP-weighted
partial likelihood. The partial likelihood was maxi-
mized, where patient i who incurred virologic failure or











where exp(b̂ITT ) is the conventional ITT hazard ratio of
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where exp(~bITT ) is the ITT hazard ratio of virologic fail-
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where exp(b̂PP) is the per-protocol hazard ratio of viro-
logic failure or death in the target population under
the additional assumption that the patients who were
sampled in the trial are exchangeable with those who
were not sampled conditional on pretreatment cov-
ariates Vi.
9 We also assume a form of positivity, that
is, within strata of Vi, all subjects in the population
have a nonzero probability of being sampled into the
trial.9
Results
Data for 761 of the 765 patients were available in the
public-use data set (380 were randomized to the three-
drug arm and 381 to the four-drug arm). The descrip-
tive statistics of baseline characteristics are reported in
Table 1 along with the characteristics of the US recently
HIV-diagnosed population in 2008–2014 from CDC
national surveillance data. ACTG A5095 included
fewer aged \26 years compared with that of the
recently HIV-diagnosed persons in the United States.
Of the 761 patients, 169 experienced virologic failure
or death (161 virologic failures and 8 deaths) during
the 2-year follow-up (88 in the three-drug arm and 81
in the four-drug arm). There were 82 dropouts during
2-year follow-up. Of the 761 patients, 59 stopped their
assigned therapy for reasons other than toxicity (25 in
the three-drug arm and 34 in the four-drug arm), and
an additional 7 patients stopped their assigned therapy
due to toxicity defined by protocol. It was inappropri-
ate to treat these patients who stopped therapy due to
toxicity as protocol deviations because these toxicities
were considered to be unavoidable deviations. Thus,
only those 59 patients who stopped therapy for reasons
other than toxicity were considered as protocol devia-
tions during follow-up. The risks for dropout and pro-
tocol deviations are depicted in Figure 1 separately. In
addition, the distribution of estimated weights is
described in Table 2.
The conventional ITT 2-year risk (unit: %) of viro-
logic failure or death from any cause in the trial was
24.5 among those who were assigned to the three-drug
arm and 23.1 among those assigned to the four-drug
arm (shown in upper left panel of Figure 2). The con-
ventional ITT 2-year risk difference (unit: %) compar-
ing the four-drug arm to the three-drug arm was 21.4
(95% CI: 28.0, 5.1), and the hazard ratio was 0.91
(95% CI: 0.68, 1.24), as shown in Table 3. The risk dif-
ference as a function of time from randomization is
depicted in the upper left panel of Figure 3, with lower
bound at 24.3. The IP-weighted ITT risk difference
that accounted for informative dropout in the trial was
22.1 (95% CI: 28.8, 4.6), and the hazard ratio was
0.89 (95% CI: 0.66, 1.20). That is, the 2-year risk of vir-
ologic failure or death if everyone in the trial were to
initiate four-drug regimen was 2.1 percentage points
lower than the risk if everyone were to initiate three-
drug regimen.
After accounting for protocol deviations in addition
to informative dropout, the IP-weighted per-protocol
2-year risk of virologic failure or death in the trial was
24.6 among the three-drug arm and 23.0 among the
four-drug arm. The per-protocol 2-year risk difference
in the trial was 21.7 (95% CI: 28.2, 5.9), and the
hazard ratio was 0.90 (95% CI: 0.67, 1.23), as shown in
Table 3. That is, the 2-year risk of virologic failure or
death if everyone in the trial were to initiate and stay
on four-drug regimen was 1.7 percentage points lower
than the risk if everyone were to initiate and stay on
three-drug regimen.
When generalizing the ITT and per-protocol effects
to the US recently HIV-diagnosed population, all the
estimates were closer to the null. The conventional ITT
2-year risk difference in the target population was 20.4
(95% CI: 26.2, 5.1), and the hazard ratio was 0.97
(95% CI: 0.70, 1.34); the IP-weighted ITT 2-year risk
difference that accounted for informative dropout in
the target population was 20.9 (95% CI: 26.9, 5.3),
and the hazard ratio was 0.95 (95% CI: 0.68, 1.32).
That is, the 2-year risk of virologic failure or death if
everyone in the US target population were to initiate
Figure 1. Risks of dropout and protocol deviations over 2 years by arm in the trial, respectively.
Solid line represents the three-drug arm, and dotted line represents the four-drug arm. The upper panel represents risks of dropout (hazard
ratio = 1.27, 95% CI: 0.82, 1.96 (comparing four-drug arm to three-drug arm)). The lower panel represents risks of protocol deviations (hazard
ratio = 1.35, 95% CI: 0.80, 2.26 (comparing four-drug arm to three-drug arm)).







persons in the USA, 2008–2014
Total N 380 381 761 296,073
Sex, no. (%)
Men 314 (83) 302 (79) 616 (81) 232,933 (79)
Age group, no. (%), y
\26 32 (8) 36 (9) 68 (9) 59,274 (20)
26–50 318 (84) 310 (81) 628 (83) 209,289 (70)a
.50 30 (8) 35 (9) 65 (9) 27,510 (9)
Intravenous drug useb, no. (%)
Ever 37 (9) 46 (12) 82 (11) 23,134 (8)
HIV-1 RNA (copies/mL)
log10
Median (IQR) 4.75 (4.43–5.43) 4.78 (4.33–5.38) 4.77 (4.38–5.41)
No. (%)
\10,000 30 (9) 41 (11) 71 (9)
10,000–100,000 201 (53) 188 (49) 389 (51)
.100,000 149 (39) 152 (40) 301 (40)
CD4 cell count, cells/mm3
Median (IQR) 209 (77–331) 223 (79–339) 214 (78–334)
No. (%)
0–50 80 (21) 72 (19) 152 (20)
51–200 102 (27) 104 (27) 206 (27)
201–500 165 (43) 168 (44) 333 (44)
.500 33 (9) 37 (10) 70 (9)
HBV/HCV infectionc, no. (%)
Positive 50 (13) 48 (13) 98 (14)
HIV, human immunodeficiency virus; IQR, interquartile range; SD, standard deviation; ZDV, zidovudine; 3TC, lamivudine; ABC, abacavir; EFV,
efavirenz; HBV, hepatitis B virus; HCV; hepatitis C virus.
aThe number and percentage of persons at age 25–54 years in the US recently HIV-diagnosed population.
bOnly one patient in ZDV/3TC + EFV arm was current intravenous drug user.
cHBV infection was defined as the presence of hepatitis B surface antigen; HCV infection was defined as the presence of hepatitis C antibody.
four-drug regimen was 0.9 percentage points lower than
the risk if everyone were to initiate three-drug regimen.
Accounting for protocol deviations in addition to infor-
mative dropout, the IP-weighted per-protocol 2-year
risk of virologic failure or death in the target popula-
tion was 24.4 in the three-drug arm and 23.7 in the
four-drug arm. The per-protocol 2-year risk difference
in the target population was 20.7 (95% CI: 26.7, 5.5),
and the hazard ratio was 0.96 (95% CI: 0.69, 1.34).
That is, the 2-year risk of virologic failure or death if
everyone in the US target population were to initiate
and stay on four-drug regimen was 0.7 percentage
Table 2. Distribution of estimated weights.
Weights Mean Standard deviation Minimum Maximum
p̂Dt 0.998 0.070 0.885 4.163
p̂Ct 0.997 0.066 0.878 3.235
p̂S 1.002 0.417 0.630 3.279
p̂D3St 0.994 0.434 0.592 8.999
p̂C3St 0.992 0.434 0.585 6.992
p̂Dt represents the estimated weight that accounts for informative dropout.
p̂Ct represents the estimated weight that accounts for informative dropout and protocol deviations.
p̂S represents the estimated weight that accounts for sampling bias.
p̂D3St represents the estimated weight that accounts for informative dropout and sampling bias.
p̂C3St represents the estimated weight that accounts for informative dropout, protocol deviations and sampling bias.
Figure 2. Risk of virologic failure or death by arms over 2 years (conventional ITT risks, dropout-weighted ITT risks, per-protocol
risks that accounted for informative dropout and protocol deviations in the A5095 trial and in the target population). ITT: intention-
to-treat; target: target population.
Solid line represents the three-drug arm, and dotted line represents the four-drug arm. Upper panels represent risks in the trial with the left panel
depicting the conventional ITT results under the independent censoring assumption, middle panel depicting the ITTresults that accounted for
informative dropout, and the right panel depicting per-protocol results that accounted for informative dropout and protocol deviation. Lower panels
represent risks in the target US recently HIV-diagnosed population with the left panel depicting the conventional ITT results that only accounted for
sampling bias, middle panel depicting the ITT results that accounted for informative dropout and sampling bias, and the right panel depicting per-
protocol results that accounted for informative dropout, protocol deviation and sampling bias.
Table 3. Risk of virologic failure or death over 2 years in the trial and in persons with HIV diagnosed in the United States during
2008–2014.












Three-drug armb 24.5 0 (REF) 1 (REF) 24.4 0 (REF) 1 (REF)
Four-drug armc 23.1 21.4 (28.0, 5.1) 0.91 (0.68, 1.24) 24.0 20.4 (26.2, 5.1) 0.97 (0.70, 1.34)
Dropout-weighted
ITTeffect
Three-drug arm 25.3 0 (REF) 1 (REF) 25.1 0 (REF) 1 (REF)
Four-drug arm 23.2 22.1 (28.8, 4.6) 0.89 (0.66, 1.20) 24.2 20.9 (26.9, 5.3) 0.95 (0.68, 1.32)
Per-protocol
effectd
Three-drug arm 24.6 0 (REF) 1 (REF) 24.4 0 (REF) 1 (REF)
Four-drug arm 23.0 21.7 (28.2, 5.9) 0.90 (0.67, 1.23) 23.7 20.7 (26.7, 5.5) 0.96 (0.69, 1.34)
RD, risk difference; CI, confidence interval.
aAssuming independent censoring.
bThree-drug standard-of-care-regimen included zidovudine, lamivudine, and efavirenz.
cFour-drug regimen including zidovudine, lamivudine, efavirenz, and abacavir.
dEffect accounted for informative dropout, protocol deviation in the trial, and additionally accounted for sampling bias in the target population.
Figure 3. Risk difference comparing four-drug arm to three-drug arm over 2 years (naı̈ve ITT risks, dropout-weighted ITT risks,
per-protocol risks that accounted for dropout and protocol deviations in the A5095 trial and in the target population). ITT:
intention-to-treat; RD: risk difference; target: target population.
Upper panels represent risk differences over 2 years in the A5095 trial with the left panel depicting the conventional ITT risk difference under the
independent censoring assumption, middle panel depicting the ITT risk difference that accounted for dropout, and the right panel depicting per-
protocol risk difference that accounted for dropout and protocol deviation. Lower panels represent risk differences over 2 years in the target US
recently HIV-diagnosed population with the left panel depicting the conventional ITT risk difference that only accounted for sampling bias, middle
panel depicting the ITTrisk difference that accounted for dropout and sampling bias, and the right panel depicting per-protocol risk difference that
accounted for dropout, protocol deviation, and sampling bias.
points lower than the risk if everyone were to initiate
and stay three-drug regimen.
Discussion
In this study, we reanalyzed the ACTG A5095 trial by
(1) estimating the ITT effect accounting for potential
informative dropout and (2) estimating the per-
protocol effect that accounted for informative dropout
and protocol deviations, and then (3) generalizing these
estimates to the US recently HIV-diagnosed target pop-
ulation. We found that there was no significant benefit
of the four-drug regimen (containing zidovudine, lami-
vudine, efavirenz, and abacavir) over the three-drug
regimen (containing zidovudine, lamivudine, and efa-
virenz) with regard to both effects in the trial and in
the target population. Our results also suggest the
adjusted ITT and per-protocol results were similar to
the conventional ITT effect, which may be due to the
relatively balanced dropout and protocol deviations in
the two arms. To our knowledge, this is the first exam-
ple of generalizing the per-protocol effect from a ran-
domized trial to a specified target population.
For this study, as a first step, we employed inverse
probability weighting6,39 (one of the g-methods) to
adjust for dependent censoring that may potentially
arise from informative dropout when estimating ITT
effect and additionally to adjust for protocol deviations
for the per-protocol effect. The dropout-weighted ITT
and per-protocol estimates are likely to differ from the
conventional ITT estimates when dropout and protocol
deviations differ by treatment arm. The mechanism of
inverse probability weighting reweights the population
over time based on the sequential weighting estimated
from time-fixed as well as time-varying prognostic fac-
tors. Such methods have been adopted in previous
work such as to estimate the per-protocol effect in the
Women’s Health Initiative estrogen-plus-progestin
trial.41 Alternative methods can also be applied to per-
protocol effect estimation. Lodi et al.42 used
g-computation (another g-method) to analyze the per-
protocol effect of immediate ART initiation versus
deferred initiation in the Strategic Timing of
Antiretroviral Treatment (START) trial and found a
potential underestimate of the benefit of immediate
initiation by conventional ITT estimation. In addition,
instrumental variable methods, which do not require
measurement of all confounders (as do inverse-prob-
ability weighting and g-computation) is an option for
per-protocol effect estimation.43,44 In double-blind ran-
domized trials, the randomization indicator is an
instrumental variable where the exclusion restriction
criteria is expected to be met (i.e. the effect of randomly
assigned treatment on the outcome is entirely mediated
through the received treatment). However, the instru-
mental variable approach requires another unverifiable
assumption of no ‘‘defiers’’ in the trial (also as known
as the monotonicity assumption).45 Furthermore, even
when these assumptions are met, instrumental variable
methods estimate the per-protocol effect among ‘‘com-
pliers’’ which may not be representative of the total
study population.
In the second step, we also adopted inverse odds
weighting (a version of inverse probability weighting) to
generalize the adjusted ITT and per-protocol effect to
the US target population. Target population estimates
are expected to differ from trial estimates when the dis-
tributions of effect modifiers differ in the trial and the
target population. That is, the external validity of ran-
domized trial results is influenced substantially by the
extent to which the prevalence of effect modifiers differs
in the trial and the target population. Similar work has
been done in previous studies. Cole and Stuart10 used
IP weighting to transport the ACTG 320 trial results to
the US HIV-infected target population.
In our analyses, we used a composite endpoint of
virologic failure and death rather than the sole virologic
failure endpoint which was used in the original pub-
lished study. We chose not to censor the deaths because
they are a competing risk,46 and we chose to make a
composite endpoint rather than model the competing
risk because there were only eight deaths.
Our results are subject to several limitations. First, in
the per-protocol effect estimation, we only accounted
for the observed protocol deviations from the publicly
available A5095 trial data. However, there is no guar-
antee that all the protocol deviations were captured. To
obtain a valid per-protocol effect, any protocol devia-
tions from assigned treatment therapy, except for clini-
cal reasons such as toxicity, should be accounted for.5
Second, it is not possible to verify the assumption that
all prognostic factors are measured. We may not cap-
ture all the common causes of protocol deviations and
outcomes, which can lead to residual confounding.
However, the trial data are of high quality, and many
important baseline and time-varying covariates were
measured. This limitation suggests that to ensure the
validity of per-protocol analyses, clinical trials should
record detailed and high-quality data on prognostic fac-
tors. Third, race, an important factor that potentially
modifies the effect of antiretroviral treatment, is una-
vailable in the public A5095 data, limiting our ability to
address external validity. Fourth, we assume correct
model specification, especially for the models used to
construct weights. To enhance model robustness, fur-
ther analyses that adopt double robust estimation can
be conducted.47 Finally, we censored patients at the
minimum of dropout or a protocol deviation for the
per-protocol analysis. Creating weights based on a com-
bination of dropout and protocol deviation assumes a
common set of variables and association between drop-
out, protocol deviation, and outcome of interest.26
However, the results that the parameter estimates for
predictors of the combined dropout and protocol devia-
tion were similar to those for dropout alone make such
assumption plausible.
In conclusion, our analyses of the ACTG A5095
trial serve as an example of using inverse probability
weighting to generalize the per-protocol effect as well
as the ITT effects to a specified target population. We
recommend conducting generalized per-protocol analy-
ses to complement conventional ITT comparisons, even
though in this case study there was little difference
between ITT and per-protocol effects, either in the
sample or in the target population. There is some evi-
dence that protocol deviations for this trial did not
matter and that results were valid for recently HIV-
diagnosed individuals. One may argue reasonably that
if subgroup effects are strong enough to make a differ-
ence for generalizability, then we should report results
by subgroups. However, covariates which individually
do not yield notable subgroup effects may combine as
detailed by Lesko et al.,9 and population-level planning
may require population-level effect estimates summar-
ized over subgroups. However, as long as positivity32 is
met and key covariates are measured, one can general-
ize results.
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